| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/01/2003 | US6541464 For therapy of osteoporosis |
| 04/01/2003 | US6541463 Inhibitors of type 5 and type 3 17β-hydroxysteroid dehydrogenase and methods for their use |
| 04/01/2003 | US6541462 Sphingomyelin enhancement of tumor therapy |
| 04/01/2003 | US6541460 Method for use of hyaluronic acid in wound management |
| 04/01/2003 | US6541457 Mammalian IAP gene family, primers, probes and detection methods |
| 04/01/2003 | US6541455 Applying to area of body having ectoparasites a composition comprising non-volatile surfactants, polar organic compounds, non-volatile fatty alcohols, and non-volatile fatty esters, for a time sufficient to trigger immersion reflex, drying |
| 04/01/2003 | US6541453 Peptide derivatives |
| 04/01/2003 | US6541255 Engraftable human neural stem cells |
| 04/01/2003 | US6541253 Diagnostics and therapy of diseases associated with HHV-8 infections |
| 04/01/2003 | US6541229 Use for better preservation of red blood cells during storage and increased viability in vivo following transfusion |
| 04/01/2003 | US6541212 Anticancer agents |
| 04/01/2003 | US6541195 Exposing a cell that expresses a conformationally defective target protein with an amount of protein stabilizer selected from amino acids, polyols, dimethylsulfoxide and deuterated water that is effective to improve phenotypic defects |
| 04/01/2003 | US6541049 Method for production of arachidonic acid |
| 04/01/2003 | US6541048 Coated chewing gum products containing an acid blocker and process of preparing |
| 04/01/2003 | US6541043 Method and synergistic composition for treating attention deficit/hyperactivity disorder |
| 04/01/2003 | US6541042 Comprising 5-25% by weight terpinen-4-ol-containing essential oils and 0.01-10% by weight tannin-containing medicinal plants or extracts thereof, used for topical treatment of cutaneous and mucous membrane affections in veterinary sector |
| 04/01/2003 | US6541040 Mixture consists of paraffins or synthetic waxes selected from montan waxes, petroleum waxes, Fischer-Tropsch waxes, polyolefin waxes, petrolatum waxes, wax alcohol and oxidates and atleast one alkali or alkaline hydroxide |
| 04/01/2003 | US6541026 Nutritional composition, methods of producing said composition and methods of using said composition |
| 04/01/2003 | US6541021 Completely implanting in a patient, at a implntation site, a controlled release drug delivery device containing a pump and a drug selected from fentanyl and a fetanyl congener, such as sufentanil for treating the pain for atleast about 3-days |
| 04/01/2003 | US6541016 Monoalkyl phosphoric esters, dialkyl phosphoric esters, and, in small amounts, trialkyl phosphoric esters or salts, based on beta-branched fatty alcohols, effective in lowering the surface tension of both polar and nonpolar liquids |
| 04/01/2003 | US6541015 Water soluble prodrug with a biologically active agent link trapped in a hydrogel and controllably released by diffusion |
| 04/01/2003 | US6541008 Vascular endothelial growth factor-like protein from orf viruses binds and activates mammalian VEGF receptor-2, and uses thereof |
| 04/01/2003 | US6541006 Administration in a daily dose to a patient for reducing or controlling blood high density lipoproteins, a formulation containing between 50mg to 3.6 gm. red yeast rice, 5mg-600 mg coenzyme Q10 and between 5 IU to 800 IU mixed tocopherols |
| 04/01/2003 | US6541005 Compositions and methods for reducing or controlling blood cholesterol, lipoproteins, triglycerides and atherosclerosis |
| 04/01/2003 | US6541003 An immunizing formulation comprising a plasmid encoding an attenuated, doxycycline-inducible proviral molecular clone of the human immunodeficiency virus type 1, and a pharmaceutical carrier |
| 04/01/2003 | US6540999 Administering to patient an antigen, a multivalent conjugate of multiple Lewisx antigen-containing oligosaccharides crosslinked to a carrier molecule and an adjuvant to stimulate a specific antibody response to above antigen |
| 04/01/2003 | US6540990 Topical application to the eye of an acetylcholine esterase inhibitor, such as a mercaptoethyltrimethylammonium salt, to improve visual acuity |
| 04/01/2003 | US6540983 A drug selected from an insulin analog, and/or amylin, a fluid propellant carrier, and a stabilizer comprising water added in addition to nascent formulation water; treating diabetes; inhalers |
| 04/01/2003 | US6540982 Medical aerosol formulation |
| 04/01/2003 | US6540978 Inhibitors of the bitter taste response |
| 04/01/2003 | US6540977 Cyanidin compositions and therapeutic and diagnostic uses therefor |
| 04/01/2003 | US6540976 Method for reducing radiation toxicity |
| 04/01/2003 | US6540715 Method and device for in-situ formulation of a medicinal solution for parenteral application |
| 04/01/2003 | US6540393 Apparatus for preparing microparticles using in-line solvent extraction |
| 04/01/2003 | CA2405918A1 Controlled release macrolide pharmaceutical formulations |
| 04/01/2003 | CA2288439C Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
| 04/01/2003 | CA2273951C Parasiticidal pyrazoles |
| 04/01/2003 | CA2270975C Stabilized sustained release tramadol formulations |
| 04/01/2003 | CA2239423C Compositions, containing bismuth and one or more antimicrobials, for the prevention and treatment of gastrointestinal disorders |
| 04/01/2003 | CA2233331C Use of sphingosylphosphorylcholine as a wound-healing agent |
| 04/01/2003 | CA2217463C Use of sulbutiamine to obtain pharmaceutical compositions which are useful in the treatment of some psychomotor and psychointellectual disorders |
| 04/01/2003 | CA2163539C N-morpholino-n-nitrosaminoacetonitrile cyclodextrin inclusion complexes |
| 04/01/2003 | CA2044676C Pharmaceutical composition for rectal administration of active principles exhibiting a prevalently topical medication action at the colon level |
| 03/31/2003 | WO2002030425A1 Preventives and remedies for complications of diabetes |
| 03/31/2003 | CA2424060A1 Preventives and remedies for complications of diabetes |
| 03/28/2003 | WO2002030871A1 Use of amino acids for treating pain |
| 03/28/2003 | WO2002030869A1 5-amino-1-pentene-3-ol substituted derivatives |
| 03/28/2003 | CA2424103A1 Substituted 5-amino-1-penten-3-ol derivatives |
| 03/28/2003 | CA2424089A1 Use of amino acids for treating pain |
| 03/28/2003 | CA2405342A1 Methods of treatment and kits comprising a growth hormone secretagogue |
| 03/28/2003 | CA2404723A1 Methods related to the a-c repeat z-sequence upstream from the aldose reductase gene |
| 03/28/2003 | CA2357982A1 Solid compositions comprising ramipril |
| 03/27/2003 | WO2003025571A1 Diagnostic markers for ischemia |
| 03/27/2003 | WO2003025228A1 Methods and compositions for treating hcap associated diseases |
| 03/27/2003 | WO2003025199A2 Mid 4460, a human tyrosine phosphatase family member and uses therefor |
| 03/27/2003 | WO2003025174A2 Regulation of human mrp1-like protein |
| 03/27/2003 | WO2003025173A1 Novel antisense oligonucleotide derivatives to hepatitis c virus |
| 03/27/2003 | WO2003025140A2 Transductin-1 and transductin-2 and applications to hereditary deafness |
| 03/27/2003 | WO2003025121A2 Igf-binding protein-derived peptide or small molecule |
| 03/27/2003 | WO2003025119A2 Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies |
| 03/27/2003 | WO2003025017A1 Cytokine receptor |
| 03/27/2003 | WO2003024986A1 6-o-carbamate-11,12-lacto-ketolide antimicrobials |
| 03/27/2003 | WO2003024976A2 Tricyclic indole derivatives as 5-ht ligands |
| 03/27/2003 | WO2003024973A1 Spirocyclic-6,7-dihydro-5h-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines |
| 03/27/2003 | WO2003024972A1 New oripavine derivatives and their uses as medicines |
| 03/27/2003 | WO2003024971A1 6,7-dihydro-5h-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines |
| 03/27/2003 | WO2003024970A1 Compounds which inhibit the release of inflammatory cytokines |
| 03/27/2003 | WO2003024969A1 Tyrosine kinase inhibitors |
| 03/27/2003 | WO2003024968A1 7-tert-butyl-3-(2-fluorophenyl)-6-(2h-(1,2,4)triazol-3-ylmethoxy)-(1,2,4)triazolo (4,3-b) pyridazine for the treatment of anxiety and convulsions |
| 03/27/2003 | WO2003024967A2 Indolizines as kinase protein inhibitors |
| 03/27/2003 | WO2003024966A1 Pteridinone derivatives as modulators of chemokine receptor activity |
| 03/27/2003 | WO2003024965A2 Heterocyclic compounds that are inhibitors of the enzyme dpp-iv |
| 03/27/2003 | WO2003024962A1 Piperidine derivatives and their use as modulators of chemokine (especially ccr3) activity |
| 03/27/2003 | WO2003024960A1 Novel use of substituted aminomethyl chromans |
| 03/27/2003 | WO2003024958A2 Processes for the preparation of 1,5-diaryl-3-substituted-pyrazoles |
| 03/27/2003 | WO2003024957A1 Benzimidazole derivatives |
| 03/27/2003 | WO2003024956A1 Method for preparing pyrimidinone compound and pharmaceutically acceptable salts thereof |
| 03/27/2003 | WO2003024953A1 Propanolamine derivative having 1,4-benzodioxane ring |
| 03/27/2003 | WO2003024952A1 Bioprecursors for percutaneous application |
| 03/27/2003 | WO2003024951A1 Flavonol and cysteine conjugates |
| 03/27/2003 | WO2003024950A1 Coumarin derivative |
| 03/27/2003 | WO2003024949A1 Dna-pk inhibitors |
| 03/27/2003 | WO2003024948A1 Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists |
| 03/27/2003 | WO2003024941A1 Naphthalene compounds and use thereof as drugs |
| 03/27/2003 | WO2003024940A1 Bifunctional chelating agent for actinium |
| 03/27/2003 | WO2003024936A1 Substituted pyrazolo compounds for the treatment of inflammation |
| 03/27/2003 | WO2003024935A2 Substituted pyrazolyl compounds for the treatment of inflammation |
| 03/27/2003 | WO2003024934A2 Derivatives of the (3s, 4ar, 6s, 8ar) 6-phenylamino-1, 2, 3, 4, 4a, 5, 6, 7, 8, 8a-decahydro isoquinoline-3-carboxylic acid as excitatory amino acid receptor antagonists for the treatment of neurological disorders and neurodegenerative diseases |
| 03/27/2003 | WO2003024933A1 2-phenyl-3-heteroarylpropionic acid derivative or salt thereof and medicine containing the same |
| 03/27/2003 | WO2003024929A1 Substituted piperidines with selective binding to histamine h3-receptor |
| 03/27/2003 | WO2003024928A2 Novel aminoazetidine, -pyrrolidine and -piperidine derivatives |
| 03/27/2003 | WO2003024926A2 Methods and compositions of novel triazine compounds |
| 03/27/2003 | WO2003024924A1 Novel compounds and compositions as cathepsin inhibitors |
| 03/27/2003 | WO2003024922A1 Hydroxyfattysulfonic acid analogs |
| 03/27/2003 | WO2003024921A1 Alkyl urea retinoid agonists i |
| 03/27/2003 | WO2003024920A1 Substituted urea retinoid agonists ii |
| 03/27/2003 | WO2003024916A1 Crystals of hydroxynorephedrine derivative |
| 03/27/2003 | WO2003024913A1 SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING NF-κB INHIBITING ACTIVITY |
| 03/27/2003 | WO2003024529A1 Simplified sarcodictyn derivatives as anti-tumor agents |
| 03/27/2003 | WO2003024528A1 Systematical administration of some oxazolidinones, e.g. linezolid, for the treatment for ocular infections |